Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

TherapeuticsMD, Inc. TXMD

· Materials · Pharmaceutical Preparations

FY2025 10-K, filed 2026-03-30
SEC EDGAR

Filing evidence summary

Mixed evidenceCoverage 4/5 core metrics

Latest reported free cash flow was -$55M.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Free cash flow was negative

    Latest reported free cash flow was -$55M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2021-12-31.

  • 6 filing risk checks flagged

    Flagged areas: Earnings quality, Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

  • Revenue expanded

    Latest reported annual revenue changed +71.6% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.

  • Operating margin improved

    Operating margin changed +201.8 percentage points from the prior annual period.

    Why this surfaced

    Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.

Core trend metrics

Latest annual revenue growth
+71.6%
as of 2025-12-31
Latest annual operating margin
-145.3%
as of 2025-12-31
Free cash flow
-$55M
as of 2021-12-31
ROIC snapshot
-2.9%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

6of 10 rule-based checks flagged
  • Earnings quality
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K/A filed 2026-04-01prior period 2024-12-31 from the same filingView filing
By geography
Revenue
  • United States$1.79M
    59.3%
    +59.6% yoy
  • Outside the United States$1.23M
    40.7%
    +92.8% yoy

Members sum to the consolidated $3.02M for this period.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-12prior period 2025-03-31 from the same filingView filing
  • Outside the United States$480K
    66.3%
    +119.2% yoy
  • United States$244K
    33.7%
    +40.2% yoy

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,122 US-listed filers · 797 in Materials
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$3M
7thof 3,301
bottom third
15thof 522
bottom third
Revenue growth
latest fiscal-year revenue vs the prior fiscal year
71.6%
93rdof 3,135
top third
85thof 473
top third
Operating margin
operating income ÷ revenue
-145.3%
14thof 2,819
bottom third
38thof 483
middle third
Net margin
net income ÷ revenue
-18.8%
25thof 3,263
bottom third
48thof 518
middle third
Return on equity
net income ÷ stockholders' equity (positive equity only)
-2.1%
40thof 3,577
middle third
73rdof 701
top third
Interest coverage
operating income ÷ interest expense (interest expense > 0)
-548.8×
4thof 819
bottom third
10thof 155
bottom third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
2.5%
48thof 2,895
middle third
64thof 476
middle third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
-7.9%
67thof 3,577
middle third
58thof 673
middle third
Balance-sheet accrual ratio
change in net operating assets ÷ average net operating assets · lower is ranked higher
-14.0%
78thof 3,059
top third
66thof 593
middle third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2025-12-31 · accruals and cash conversion as filed
Cash conversion
-
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
-7.9%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
-14.0%
change in net operating assets ÷ average net operating assets
Cash-backed years
3 of 5
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
0.08×
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 28 changed periods, 26 largest shown
Line itemPeriodFirst reportedLatest filingChangeFilings
Diluted shares
WeightedAverageNumberOfDilutedSharesOutstanding
fiscal year 2024-12-3111,532 shares
10-K 2025-03-27
11,532,000 shares
10-K/A 2026-04-01
+99900.0%first · latest · 3 filings carry it
Basic shares
WeightedAverageNumberOfSharesOutstandingBasic
fiscal year 2024-12-3111,532 shares
10-K 2025-03-27
11,532,000 shares
10-K/A 2026-04-01
+99900.0%first · latest · 3 filings carry it
Intangibles
IntangibleAssetsNetExcludingGoodwill
balance at 2020-12-31$5.25M
10-K 2021-03-04
$41.4M
10-K 2022-03-23
+689.8%first · latest · 5 filings carry it
Revenue
RevenueFromContractWithCustomerIncludingAssessedTax
fiscal year 2023-12-31$300K
10-K 2024-03-29
$1.3M
10-K 2025-03-27
+334.0%first · latest
Cash
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
balance at 2022-03-31$30.4M
10-Q 2022-05-16
$65.1M
10-Q 2023-05-15
+114.3%first · latest
Gross profit
GrossProfit
quarter 2022-06-30$23.8M
10-Q 2022-08-15
$0
10-Q 2023-08-14
-100.0%first · latest
Gross profit
GrossProfit
quarter 2022-09-30$17.1M
10-Q 2022-11-14
$0
10-Q 2023-11-14
-100.0%first · latest
Diluted shares
WeightedAverageNumberOfDilutedSharesOutstanding
fiscal year 2023-12-3110,441,000 shares
10-K 2024-03-29
10,441 shares
10-K 2025-03-27
-99.9%first · latest
Diluted shares
WeightedAverageNumberOfDilutedSharesOutstanding
quarter 2025-03-3111,552,000 shares
10-Q 2025-05-13
11,552 shares
10-Q 2026-05-12
-99.9%first · latest
Basic shares
WeightedAverageNumberOfSharesOutstandingBasic
fiscal year 2023-12-3110,441,000 shares
10-K 2024-03-29
10,441 shares
10-K 2025-03-27
-99.9%first · latest
Basic shares
WeightedAverageNumberOfSharesOutstandingBasic
quarter 2025-03-3111,552,000 shares
10-Q 2025-05-13
11,552 shares
10-Q 2026-05-12
-99.9%first · latest
Gross profit
GrossProfit
fiscal year 2021-12-31$68.1M
10-K 2022-03-23
$1.17M
10-K 2023-04-07
-98.3%first · latest
Revenue
RevenueFromContractWithCustomerIncludingAssessedTax
fiscal year 2021-12-31$87M
10-K 2022-03-23
$2.57M
10-K 2023-04-07
-97.0%first · latest
Intangibles
IntangibleAssetsNetExcludingGoodwill
balance at 2021-12-31$40.3M
10-K 2022-03-23
$7.14M
10-K 2023-04-07
-82.3%first · latest · 5 filings carry it
Cash
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
balance at 2022-06-30$37.6M
10-Q 2022-08-15
$65.1M
10-Q 2023-08-14
+73.4%first · latest
Cash
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
balance at 2023-06-30$49.3M
10-Q 2023-08-14
$13.7M
10-Q 2024-08-12
-72.2%first · latest
Cash
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
balance at 2022-09-30$38.3M
10-Q 2022-11-14
$65.1M
10-Q 2023-11-14
+69.9%first · latest
Operating income
OperatingIncomeLoss
quarter 2025-03-31-$871K
10-Q 2025-05-13
-$1.28M
10-Q 2026-05-12
-47.1%first · latest
Operating income
OperatingIncomeLoss
fiscal year 2021-12-31-$140M
10-K 2022-03-23
-$79.6M
10-K 2023-04-07
+43.1%first · latest
Operating income
OperatingIncomeLoss
quarter 2022-03-31-$26.2M
10-Q 2022-05-16
-$17.9M
10-Q 2023-05-15
+31.9%first · latest
Operating income
OperatingIncomeLoss
quarter 2022-09-30-$20.7M
10-Q 2022-11-14
-$14.5M
10-Q 2023-11-14
+30.0%first · latest
Operating income
OperatingIncomeLoss
fiscal year 2024-12-31-$4.76M
10-K 2025-03-27
-$6.11M
10-K/A 2026-04-01
-28.4%first · latest · 3 filings carry it
Cash
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
balance at 2022-12-31$64.9M
10-K 2023-04-07
$49.3M
10-K 2025-03-27
-24.0%first · latest · 4 filings carry it
Operating income
OperatingIncomeLoss
quarter 2022-06-30-$18.8M
10-Q 2022-08-15
-$14.9M
10-Q 2023-08-14
+21.1%first · latest
Operating income
OperatingIncomeLoss
quarter 2024-06-30-$2.44M
10-Q 2024-08-12
-$2.79M
10-Q 2025-08-12
-14.3%first · latest
Interest expense
InterestExpenseDebt
fiscal year 2024-12-31$9.5K
10-K 2025-03-27
$10K
10-K/A 2026-04-01
+5.3%first · latest · 3 filings carry it

4 share-count periods re-presented for a stock split (1-for-50) are listed apart from restatements and not counted above.

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

debt, leases, revenue, segments, contingencies, taxes and more · the filer's own words
Latest annual report10-K/A FY2025 · filed 20260401View filing
Commitments and contingencies · 16,013 characters as filed

7. Commitments and contingencies Leases In October 2018, we entered into a lease for executive, administrative, operations and sales offices in Boca Raton, Florida. The lease includes 62,748 rentable square feet, or the full premises, of which the lease on 7,561 square feet commenced in 2018 and the lease on 48,651 square feet commenced in August 2019, or the full premises commencement date. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which commenced in May 2020. The lease will expire 11 years after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. As a result of shifting our business to become a license company and terminating our employees, we have sublet all of our headquarters. We anticipate that sublease income will approximate the amounts due under our existing leases, therefore no impairment of the right of use asset was recorded in 2025. For 2025 and 202

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Debt · 244 characters as filed

6. Interest and financing costs Interest income was $150 thousand for the year ended 2025, compared to $145 thousand for the year ended 2024. Interest expense and other financing costs were $8 thousand in 2025, compared to $10 thousand in 2024.

DebtDisclosureTextBlock

Income taxes · 5,054 characters as filed

10. Income taxes The components of loss from continuing operations before income tax for the years ended December 31, 2025 and 2024 is as follows (in thousands): Year Ending December 31, 2025 2024 United States $ (653 ) $ (2,343 ) Our (loss) income allocated between continuing operations and discontinued operations before income taxes is as follows (in thousands): Year Ending December 31, 2025 2024 Loss from continuing operations before income taxes $ (653 ) $ (2,343 ) (Loss) income from discontinued operations before income taxes $ 84 $ 131 For the year ended December 31, 2025, there was no provision for income taxes in continuing and discontinued operations, current or deferred. For the year ended December 31, 2024, the Company recorded an income tax benefit of $31 thousand, as reflected in the rate reconciliation table below. As of December 31, 2025, we had a federal net operating loss (NOL) carryforwards of $584.6 million, which is available to offset future taxable income. Approximately $27.6 million of the federal NOLs can be carried forward for 20 years and will begin to expire in 2035. The remaining $557.1 million can be carried forward indefinitely. In the event of future income, the NOL deduction arising from NOLs generated in taxable years beginning in 2021 will be limited to 80% of the excess taxable income. The Company experienced an ownership change pursuant to IRC Sec. 382 in 2022. As a result, our NOLs carryforward as of December 31, 2022 is limited. A reconci

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

New accounting pronouncements · 4,203 characters as filed

B. New accounting standards Recently Issued Accounting Standards Adopted During the Fiscal Year As of December 2025, we have adopted the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU No. 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The Company adopted this accounting standard update for the year ended December 31, 2025. Recently Issued Accounting Standards Not Yet Adopted In July 2025, the FASB issued Accounting Standards Update (ASU) No. 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient related to the estimation of expected credit losses for accounts receivable and current contract assets that arise from transactions accounted for under Accounting Standards Codification (ASC) 606, Revenue Recognition. ASU No. 2025-05 requires an entity to disclose whether it has elected to use the practical expedient. An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collections are evaluated. The requirements of ASU No. 2025-05 are effective for annual periods beginning after December 15, 2025, and interim periods beginning in the first quarter of 2026. Early adopt

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

Related parties · 1,922 characters as filed

12. Related parties On August 23, 2022, we appointed Mr. Justin Roberts as a director to fill a newly created vacancy on our Board of Directors. Mr. Roberts was elected to serve as a director at our combined 2022 and 2023 Annual Meeting held on June 26, 2023. Mr. Roberts will serve until our next Annual Meeting of Stockholders or until his successor is duly elected or appointed or his earlier death or resignation. As a director of our Company, Mr. Roberts is entitled to receive compensation in the same manner as our other non-employee directors, described in the section entitled Director Compensation in our Amendment No. 1 to Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on May 1, 2023, but he has elected not to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as a Partner of Rubric. On July 29, 2022, September 30, 2022, October 28, 2022, and May 1, 2023, we entered into subscription agreements with Rubric. On December 30, 2022, in accordance with the terms of the Certificate of Designation, we redeemed all 29,000 outstanding shares of Series A Preferred Stock previously issued to affiliates of Rubric at a purchase price of $1,333 per share. also paid certain affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into between us and Rubric. On June 29, 2023, we issued and sold 312,5

RelatedPartyTransactionsDisclosureTextBlock · excerpt; the full note is in the filing

Revenue recognition · 2,915 characters as filed

9. Revenue Pursuant to the Mayne License Agreement, the Company granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories. Pursuant to the Mayne License Agreement, Mayne Pharma agreed to make one-time, milestone payments to the Company of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year reach $300.0 million. Further, Mayne Pharma agreed to pay to the Company royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first $80 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

Segment reporting · 789 characters as filed

14. Segment Reporting The Company operates in one segment. Accordingly, the Companys License revenue, Net loss, and Total assets reflect the revenue, loss, and assets of the Companys single segment, respectively. The Companys Chief Executive Officer is the chief operating decision maker (CODM). The CODM uses Net loss in assessing the performance and in determining the allocation of resources of the Companys reportable segment. The CODM is regularly provided expense information consistent with the expense categories presented in the Companys Consolidated Statements of Operations The following tables present total revenue of the Company by geographic location. As of December 31, 2025 2024 License revenue United States $ 1,792 $ 1,123 Non-U.S. 1,230 638 Total $ 3,022 $ 1,761

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

Subsequent events · 27 characters as filed

15. Subsequent Events None.

SubsequentEventsTextBlock

Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.